Evan Delgado, PhD

S433, 200 Lothrop St
Pittsburgh, PA 15261

Liver-Related Work

My research aims to challenge the unmet need of effective targeted therapies for Hepatocellular Carcinoma (HCC). HCC is the 5th most common cause of cancer-related death in the United States with an estimated 32,000 annual deaths. The standard of care for HCC as established by the IMBrave150 trial is a combination of the PD-L1 inhibitor, Atezolizumab, and an antiangiogenic, Bevacizumab. While this combination extends overall survival to 19.2 months in unresectable HCC, only 52% of patients survive to 18 months. Due to the molecular heterogeneity of HCC, whether a patient responds to therapeutic intervention strongly depends on underlying molecular drivers. It has been my goal to study these mechanisms to improve therapeutic efficacy in a personalized approach. For example, my work has identified that IQGAP1, a scaffold protein, potentiates hepatocellular carcinogenesis in a subset of patients. Studying the dysregulation in molecules such as IQGAP1 will improve our knowledge of effective personalized therapies targeted for specific HCCs. I plan to implement these findings with the goal of improving the translatability of pre-clinical animal models for HCC. An explanation for the current state of HCC therapeutics may be the ineffective translation of pre-clinical animal models to human disease. In fact, only about 1/3 of therapeutic approaches generated using animal models move to Phase I trials, and, of those that make it, only 8% pass. Improvements in this space are desperately needed to translate findings into practical therapeutic options. My goal is to develop a model of HCC that merges molecular, immunological, and clinical information to better represent the human condition so novel therapeutic strategies are effectively translated into patients.


View Dr. Delgado’s publications on PubMed


Past, current and ongoing collaborations with Drs. Andrew Duncan, Sayee Anakk, Hanna Erickson, Reza Zarnegar, Alex Soto-Gutierrez, Paul Monga, Amaia Lujambio, Sungjin Ko, and Aatur Singhi


Hepatocyte and non-parenchymal cell isolations

Research Assistant Professor
Department of Pathology